Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections

International Journal of Antimicrobial Agents

Volumn 28, Issue SUPPL. 1, 2006, Pages 35-41

  Mazzei, Teresita ^a   Cassetta, Maria Iris ^a   Fallani, Stefania ^a   Arrigucci, Silvia ^a   Novelli, Andrea ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Fosfomycin; Post antibiotic effect; Time kill kinetic studies; Urinary tract infection

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; FOSFOMYCIN TROMETAMOL; GLYCOPEPTIDE; KETOLIDE; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; NALIDIXIC ACID; NITROFURANTOIN; NORFLOXACIN; OXAZOLIDINONE DERIVATIVE; PIPEMIDIC ACID; PIVMECILLINAM; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG TOLERABILITY; ENTEROCOCCUS; HUMAN; IN VITRO STUDY; INFECTION COMPLICATION; INFECTION PREVENTION; INFECTION RISK; LIVER TOXICITY; LUNG TOXICITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; PROTEUS MIRABILIS; RISK REDUCTION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI;

ANTI-INFECTIVE AGENTS; BETA-LACTAMS; FLUOROQUINOLONES; FOSFOMYCIN; HUMANS; NITROFURANTOIN; QUINOLONES; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; URINARY TRACT INFECTIONS;

EID: 33746738765     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.05.019     Document Type: Article

References (37)

1. Chambers ST. Cystitis and urethral syndromes. In: Armstrong D, Cohen J, editors. Mosby, Harcourt Publishers Ltd, London, UK. Infection Diseases; Section 2: 57.1-57.8, 1999.
2. Nicolle L.E. Resistant pathogens in urinary tract infections. J Am Geriatr Soc 50 Suppl. 7 (2002) S230-S235
3. Gupta K., Hooton T.M., and Stamm W.E. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 135 (2001) 41-50
4. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-10
5. Rodvold K.A. Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside. Pharmacotherapy 21 Part 2 (2001) 319S-330S
6. McKinnon P.S., and Davis S.L. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious disease. Eur J Clin Microbiol Infect Dis 23 (2004) 271-288
7. Andes D., and Craig W.A. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19 (2002) 261-268
8. Maglio D., and Nicolau D.P. The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens. Methods Find Exp Clin Pharmacol 26 (2004) 781-788
9. Speciale A.M., Nicoletti G., Torrisi C., et al. Prevalence and antibiotic resistance of the most important urinary pathogens responsible for non complicated cystitis in women: the IceaA2 study. Giornale Italiano di Microbiologia Medica Odontoiatrica e Clinica IX (2005) 3-18 [in Italian]
10. Fadda G., Nicoletti G., Schito G.C., and Tempera G. Antimicrobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines. J Chemother 17 (2005) 251-257
11. Mendez J.L., Nadrous H.F., Hartman T.E., and Ryu J.H. Chronic nitrofurantoin-induced lung disease. Mayo Clin Proc 80 (2005) 1298-1302
12. Nickel J.C. Management of urinary tract infections: historical perspective and current strategies. Part 2. Modern management. J Urol 173 (2005) 27-32
13. Klepser M.E., Marangos M.N., Patel K.B., Nicolau D.P., Quintiliani R., and Nightingale C.H. Clinical pharmacokinetics of newer cephalosporins. Clin Pharmacokinet 28 (1995) 361-384
14. Lode H., Fassbender M., Schaberg T., Borner K., and Koeppe P. Comparative pharmacokinetics of the new oral cephalosporins. Drugs 47 Suppl. 3 (1994) 10-19
15. Periti P., Mazzei T., Mini E., and Novelli A. Ceftibuten, clinical pharmacology and chemotherapy. Farmaci Terapia IX Suppl. 1 (1992)
16. Perry C.M., and Brogden R.N. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 52 (1996) 125-158
17. Graninger W. Pivmecillinam-therapy of choice for lower urinary tract infection. Int J Antimicrob Agents 22 Suppl. 2 (2003) 73-78
18. Appelbaum P.C., and Hunter P.A. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 16 (2000) 5-15
19. Peterson L.R. Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clin Infect Dis 33 Suppl. 3 (2001) S180-S186
20. Von Rosenstiel N., and Adam D. Quinolone antibacterials. An update of their pharmacology and therapeutic use. Drugs 47 (1994) 872-901
21. Mazzei T., Novelli A., Reali E.F., et al. Farmacocinetica e penetrazione tissutale della oflossocina. Farmaci & Terapia 4 (1987) 244-249 [Abstract in Italian]
22. Novelli A., Cassetta M.I., Fallani S., and Periti P. Clinical pharmacokinetics and tissue penetration of ciprofloxacin after a single or multiple oral dose of 250 or 500 mg. Eur J Clin Microbiol Infect Dis 20 (1991) 367-369
23. Schaeffer A.J. The expanding role of fluoroquinolones. Am J Med 113 Suppl. 1A (2002) 45S-54S
24. Pickerill K.E., Paladino J.A., and Schentag J.J. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy 20 (2000) 417-428
25. Picollo R., Brion N., Gualano V., et al. Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneimittelforschung 53 (2003) 201-205
26. Preston S.L., Drusano G.L., Berman A.L., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. J Am Med Assoc 279 (1998) 125-129
27. Schentag J.J. Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models. Clin Infect Dis 31 Suppl. 2 (2000) S40-S44
28. Ball P. Future of the quinolones. Semin Respir Infect 16 (2001) 215-224
29. Novelli A., Mini E., and Mazzei T. Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections. Eur Respir Monographs 28 (2004) 229-254
30. Patel S.S., Balfour J.A., and Bryson H.M. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 53 (1997) 637-656
31. Fuchs P.C., Barry A.L., and Brown S.D. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother 43 (1999) 137-140
32. Garcia-Rodriguez J.A., Trujillano Martin I., Baquero F., et al. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study. J Chemother 9 (1997) 394-402
33. Novelli A., and Periti E. How to select a drug for the treatment of bacteriuria in pregnancy. New Trends Gynecol Obstet 6 (1990) 189-193
34. Krcmery S., Hromec J., and Demesova D. Treatment of lower urinary tract infection in pregnancy. Int J Antimicrob Agents 17 (2001) 279-282
35. National Committee for Clinical Laboratory Standards (NCCLS). Antimicrobial susceptibility testing. 3rd ed. (1991), NCCLS, Villanova, PA
36. Espinoza A.M., Chin N.X., Novelli A., and Neu H.C. Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob Agents Chemother 32 (1988) 663-670
37. Naber KG, Bishop MC, Bjerklund-Johansen TE, et al. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines on the management of urinary and male genital tract infections. Eur Assoc Urol; 2006.